LICENSING DEAL OF THE YEAR

Deals considered here are those that involve the licensing of a particular drug, project or group of R&D assets from one company to another for further development and/ or marketing. (This category does not include more complex, broad partnerships between companies, for example to explore particular therapeutic strategies or mechanisms of action.)

The judges will look at all aspects from monetary and strategic value to the benefits they give to both sides. To qualify, licensing deals must have been closed during the qualifying period of July 1, 2023 - June 30, 2024).

To enter this category, please answer the following:

- Outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
- Monetary value of the deal in up-front and milestone payments.
- Countries and indications included in the deal and does it allow any party to enter new markets?
- Strategic value of the licensed product to the licensee/ licensor's business.
- Please explain how the licensed product was the best possible candidate to complement the rest of the licensee's pipeline or particular disease franchise, or how it fit into the licensor's business strategy.

Please complete the contact and entry sections and email to Natalia Kay, Senior Events Manager.
E: Natalia.Kay@citeline.com

Details of person submitting the entry:

Entering Company

Twitter handle of the entering company

Website of the entering company

Name of the person submitting this entry form

References
Include any links to online references that may support your entry

Organization of the person submitting this entry form *(if different from 'Entering Company')*

Email address

Entry summary: (approx. 250 words)

Please enter a summary of your entry, this may be used in Awards publicity material so please do not include any confidential information.

Entry: (approx. 1500 words)

Please use this box to submit your entry, referring to the questions in the category criteria.